Coultreon Biopharma Appoints Prista Charuworn As CMO

With COL-5671 moving toward Phase II studies in ulcerative colitis and psoriasis, Coultreon Biopharma's appointment of Prista Charuworn, MD as Chief Medical Officer signals a deliberate push to close the gap between first-in-human data and pivotal-stage manufacturing readiness. For QA directors and regulatory leads tracking clinical-stage immunology pipelines, the hire reflects a pattern: clinical-stage biotechs recruiting Big Pharma CMO talent ahead of the process validation and IND amendment cycles that Phase II entry demands.

Dr. Charuworn brings fellowship training in gastroenterology and transplant hepatology from Stanford, alongside industry roles at Gilead, AstraZeneca, Amgen, and Zai Lab, where she most recently served as Global Head of Neuroscience and Immunology. Her development portfolio spans inflammatory bowel disease and dermatologic indications, two of the therapeutic areas COL-5671 is now being positioned to address. That cross-indication depth is directly relevant to the adaptive trial designs and endpoint selection decisions that will shape the compound's regulatory submissions.

COL-5671 is a highly selective SIK3 inhibitor designed for once-daily oral dosing. The completed first-in-human study returned a favorable safety profile alongside pharmacokinetic and pharmacodynamic data that Coultreon characterizes as supportive of broad applicability across immune-mediated conditions. For plant heads and CMC teams, the oral small-molecule format carries distinct implications: commercial-scale synthesis, dissolution specifications, and 21 CFR Part 211 process validation timelines will need to be scoped in parallel with the Phase II protocol design, not after it.

CEO Pierre Raboisson framed the appointment as a milestone toward Phase II progression, citing Charuworn's disease biology expertise as central to generating timely, high-quality clinical data. The language tracks with an organization building toward a regulatory package, not just a proof-of-concept readout.

The Phase II entry timeline for COL-5671 in ulcerative colitis and psoriasis will serve as the first measurable checkpoint for Charuworn's clinical strategy and the manufacturing scale-up decisions that follow it.

Source: Coultreon Biopharma via GlobeNewswire, August 18, 2026.